Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target
- PMID: 24711006
- DOI: 10.1007/s10875-014-0032-5
Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target
Abstract
The top-down, reductionist approach of the past three decades has resulted in remarkable progress in identifying genes and proteins involved in Alzheimer's disease (AD), including β-amyloid (Aβ) peptides and tau protein. Recently, a number of genes of the innate immune pathway have been identified as AD risk factors and several microglial proteins have been shown to be chronically activated in AD brains. Together, these observations suggest a crucial role for neuroinflammation in AD pathogenesis and emerging evidence suggests that neuroinflammation is both a cause and a consequence of AD. Epidemiological studies show that long-term users of anti-inflammatory drugs are protected from AD but anti-inflammatory treatment in mild AD patients has not been successful. These observations suggest that anti-inflammatory treatment is likely to be successful if initiated prior to the onset of neurological symptoms. Finally, after the remarkable success of the reductionist approach, a complimentary bottom-up systems approach is necessary to gain a better understanding of the highly complex, multifactorial nature of AD pathogenesis.
Similar articles
-
[Development of antibodies for immunotherapy of Alzheimer's disease].Rinsho Shinkeigaku. 2012;52(11):1168-70. doi: 10.5692/clinicalneurol.52.1168. Rinsho Shinkeigaku. 2012. PMID: 23196552 Japanese.
-
Immunotherapy for Alzheimer's disease.Acta Biochim Biophys Sin (Shanghai). 2012 Oct;44(10):807-14. doi: 10.1093/abbs/gms065. Epub 2012 Aug 16. Acta Biochim Biophys Sin (Shanghai). 2012. PMID: 22899646 Review.
-
The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease.Immunol Cell Biol. 2020 Jan;98(1):28-41. doi: 10.1111/imcb.12301. Epub 2019 Nov 20. Immunol Cell Biol. 2020. PMID: 31654430 Review.
-
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Immunotherapy. 2012. PMID: 22339463 Review.
-
Targeting microglia for the treatment of Alzheimer's Disease.Glia. 2016 Oct;64(10):1710-32. doi: 10.1002/glia.22988. Epub 2016 Apr 21. Glia. 2016. PMID: 27100611 Review.
Cited by
-
Shunaoxin dropping pill, a Chinese herb compound preparation, attenuates memory impairment in d-galactose-induced aging mice.RSC Adv. 2018 Mar 13;8(19):10163-10171. doi: 10.1039/c7ra13726e. eCollection 2018 Mar 13. RSC Adv. 2018. PMID: 35540463 Free PMC article.
-
Long-Term Administration of Vespa velutina nigrithorax Venom Ameliorates Alzheimer's Phenotypes in 5xFAD Transgenic Mice.Toxins (Basel). 2023 Mar 6;15(3):203. doi: 10.3390/toxins15030203. Toxins (Basel). 2023. PMID: 36977094 Free PMC article.
-
Glio-vascular changes during ageing in wild-type and Alzheimer's disease-like APP/PS1 mice.Brain Res. 2015 Sep 16;1620:153-68. doi: 10.1016/j.brainres.2015.04.056. Epub 2015 May 9. Brain Res. 2015. PMID: 25966615 Free PMC article.
-
Neuroprotective Effects of Cistanches Herba Therapy on Patients with Moderate Alzheimer's Disease.Evid Based Complement Alternat Med. 2015;2015:103985. doi: 10.1155/2015/103985. Epub 2015 Sep 7. Evid Based Complement Alternat Med. 2015. PMID: 26435722 Free PMC article.
-
Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings.J Alzheimers Dis Rep. 2019 Jul 2;3(1):179-218. doi: 10.3233/ADR-190125. J Alzheimers Dis Rep. 2019. PMID: 31435618 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous